Terns Pharmaceuticals, Inc. (TERN)

NMS – Real vaqt narxi. Valyuta: USD

52.92

-0.25 (-0.47%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

52.93

+0.01 (0.02%)

Bozordan keyin: Mar 27, 2026, 7:44 PM EDT

Kompaniya haqida

Terns Pharmaceuticals, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, onkologiya va semirishni davolash uchun kichik molekulali mahsulot nomzodlarini ishlab chiqadi. Kompaniya surunkali miyeloid leykemiya (SML) uchun 1-bosqichli klinik sinovda bo'lgan allosterik BCR-ABL tirozin kinaza inhibitörini (TKI) ishlab chiqadi, bu suyak ilig'ida boshlanadigan saratonning bir turi. Shuningdek, u MASH bilan bog'liq metabolik disfunksiya steatohepatitini (MASH) davolash uchun jigar taqsimoti va metabolik barqarorligi yaxshilangan qalqonsimon bez gormoni beta retseptorining agonisti bo'lgan TERN-501; va semirish uchun og'iz orqali yuborilishi uchun mo'ljallangan kichik molekulali Glyukagon-Like Peptide-1 retseptor agonisti dasturi TERN-601; hamda semirish uchun kichik molekulali glyukozaga bog'liq insulinotrop polipeptid retseptorining (GIPR) modulyatorlari bo'lgan TERN-800 seriyasini ishlab chiqadi. Kompaniya 2016-yilda tashkil etilgan va Kaliforniyaning Foster Siti shahrida joylashgan.

Asosiy rahbarlar

Ism	Lavozim
Dr. Emil T. Kuriakose M.D.	Chief Medical Officer
Dr. Jeffrey R. Jasper Ph.D.	SVP & Senior Distinguished Research Fellow
Mr. Andrew W. Gengos	CFO & Head of Corporate Development
Mr. Scott Harris	Chief Development & Operations Officer
Ms. Amy L. Burroughs M.B.A.	CEO & Director
Ms. Caryn Gordon McDowell J.D.	Chief Legal Officer
Ms. Debra Sieminski	Senior Vice President of Medical Affairs